phase 3 study which assessed the safety and efficacy of Zerbaxa compared with meropenem in 726 adult patients diagnosed with either ventilated HABP or VABP requiring intravenous antibiotic therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback